 Greenwich LifeSciences NASDAQ: GLSI shares spiked 1,900 higher Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium. Greenwich LifeSciences is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients. 